GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries

GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases.
Source: GSK news - Category: Pharmaceuticals Source Type: news